MX371068B - ((3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil ]pirrolidin-3-ona o-metiloxima cristalina y métodos de uso de la misma. - Google Patents
((3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil ]pirrolidin-3-ona o-metiloxima cristalina y métodos de uso de la misma.Info
- Publication number
- MX371068B MX371068B MX2016016751A MX2016016751A MX371068B MX 371068 B MX371068 B MX 371068B MX 2016016751 A MX2016016751 A MX 2016016751A MX 2016016751 A MX2016016751 A MX 2016016751A MX 371068 B MX371068 B MX 371068B
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline
- methyloxime
- pyrrolidin
- biphenyl
- hydroxymethyl
- Prior art date
Links
- OLUJSZLBWZWGJT-KOXKPCSVSA-N [(2s,4e)-2-(hydroxymethyl)-4-methoxyiminopyrrolidin-1-yl]-[4-(2-methylphenyl)phenyl]methanone Chemical compound C1C(=N/OC)/C[C@@H](CO)N1C(=O)C1=CC=C(C=2C(=CC=CC=2)C)C=C1 OLUJSZLBWZWGJT-KOXKPCSVSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 102100028139 Oxytocin receptor Human genes 0.000 abstract 1
- 101710103206 Oxytocin receptor Proteins 0.000 abstract 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 abstract 1
- 230000032692 embryo implantation Effects 0.000 abstract 1
- 210000001161 mammalian embryo Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462020076P | 2014-07-02 | 2014-07-02 | |
| PCT/EP2015/062881 WO2016000920A1 (en) | 2014-07-02 | 2015-06-10 | Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016016751A MX2016016751A (es) | 2017-08-08 |
| MX371068B true MX371068B (es) | 2020-01-15 |
Family
ID=53434312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016751A MX371068B (es) | 2014-07-02 | 2015-06-10 | ((3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil ]pirrolidin-3-ona o-metiloxima cristalina y métodos de uso de la misma. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9718772B2 (https=) |
| EP (2) | EP3753921A1 (https=) |
| JP (4) | JP2017519015A (https=) |
| KR (1) | KR102470283B1 (https=) |
| CN (3) | CN106795110A (https=) |
| AU (1) | AU2015283133B2 (https=) |
| CA (1) | CA2953722C (https=) |
| EA (2) | EA031353B1 (https=) |
| ES (1) | ES2774789T3 (https=) |
| IL (1) | IL249652B (https=) |
| MX (1) | MX371068B (https=) |
| UA (1) | UA122210C2 (https=) |
| WO (1) | WO2016000920A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| AU2015283133B2 (en) | 2014-07-02 | 2019-05-16 | ObsEva SA | Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity |
| JP6933322B2 (ja) | 2016-01-04 | 2021-09-08 | メルク セローノ エス．エー． | ヒドロキシプロピルチアゾリジンカルボキサミド誘導体のｌ−バリネート及びその塩形態、結晶多形 |
| CN115590849A (zh) | 2016-07-21 | 2023-01-13 | 奥布赛瓦股份公司（Ch） | 促进胚胎植入和预防流产的催产素拮抗剂给药方案 |
| CA3149898A1 (en) | 2019-09-03 | 2021-03-11 | Ernest Loumaye | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| JP7083793B2 (ja) * | 2019-09-10 | 2022-06-13 | Ｊｆｅケミカル株式会社 | パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法 |
| WO2021160597A1 (en) | 2020-02-10 | 2021-08-19 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
| EP4313061A4 (en) * | 2021-03-31 | 2025-03-05 | The Board of Trustees of the Leland Stanford Junior University | FORMULATIONS FOR PROLONGATION OF GESTATION AND FOR COMPLICATIONS OF MENSTRUATION OR GESTATION |
| WO2026018221A1 (en) * | 2024-07-18 | 2026-01-22 | ReproNovo SA | Crystalline compositions for improving embryo implantation and methods of using the same |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU120988A (en) | 1988-06-23 | 1990-06-30 | Lek Tovarna Farmacevtskih | Process for preparing new dispersion pills of cimetidine |
| YU183988A (en) | 1988-09-30 | 1990-08-31 | Lek Tovarna Farmacevtskih | Process for preparing dispersion pills of dihydroergotoxine |
| US5089043A (en) | 1989-11-09 | 1992-02-18 | Shionogi & Co., Ltd. | Heterocyclic oxy-phenoxyacetic acid derivatives and their use as herbicides |
| US5889001A (en) | 1993-07-29 | 1999-03-30 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| JP3534903B2 (ja) | 1995-06-09 | 2004-06-07 | 鐘淵化学工業株式会社 | １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法 |
| GB9603699D0 (en) | 1996-02-21 | 1996-04-17 | Boots Co Plc | Therapeutic composition |
| US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| DK1235558T3 (da) | 1999-12-09 | 2006-10-09 | Reckitt Benckiser Healthcare | Sammenpresset tabletsammensætning, der omfatter et NSAID |
| AU2001256209B2 (en) | 2000-03-27 | 2006-02-16 | Merck Serono Sa | Pharmaceutically active pyrrolidine derivatives |
| ATE329899T1 (de) | 2000-03-27 | 2006-07-15 | Applied Research Systems | Pharmazeutisch wirksame pyrrolidin-derivate als bax-inhibitoren |
| TW536751B (en) | 2000-07-14 | 2003-06-11 | Nitto Denko Corp | Cleaning sheet, conveying member using the same, and substrate processing equipment cleaning method using them |
| EP1829861A3 (en) | 2001-03-20 | 2009-01-21 | Laboratoires Serono SA | Pyrrolidine ester derivatives active as oxytocin antagonists |
| KR200245627Y1 (ko) * | 2001-05-15 | 2001-10-15 | 김병두 | 전기 가열부재가 부착된 냄비 |
| UA75145C2 (en) | 2001-06-18 | 2006-03-15 | Applied Research Systems | Pyrrolidine oxadiazole and thiadiazole derivatives, pharmaceutical composition based thereon, a method for producing thereof (variants) |
| JP2003192582A (ja) | 2001-12-12 | 2003-07-09 | Merck Patent Gmbh | ナプロキセンナトリウムを含む速放性錠剤 |
| UA78058C2 (en) | 2002-07-05 | 2007-02-15 | Applied Research Systems | Pyrrolidine derivative as oxitocin antagonists |
| JP4773335B2 (ja) | 2003-02-27 | 2011-09-14 | メルク セローノ ソシエテ アノニム | オキシトシンアンタゴニストとしてのピロリジン誘導体 |
| DK1725526T3 (da) | 2004-02-26 | 2008-03-03 | Serono Lab | Fremgangsmåde til fremstilling af pyrrolidinoximer |
| GB2411355B (en) | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
| US20080318847A1 (en) | 2005-05-10 | 2008-12-25 | Ferring International Center Sa | Use of Antagonist of Oxytocin and/or Vasopressin in Assisted Reproduction |
| JP2008189732A (ja) | 2007-02-01 | 2008-08-21 | Fujifilm Corp | セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置 |
| BRPI0817927A2 (pt) | 2007-10-01 | 2015-04-07 | Lesvi Laboratorios Sl | Comprimidos orodispersiveis |
| US9201077B2 (en) | 2009-07-27 | 2015-12-01 | Colorado State University Research Foundation | Direct enzyme immunoassay for measurement of serum progesterone levels |
| EP2922475A1 (en) | 2012-11-26 | 2015-09-30 | Ferring BV | Method and system for diagnosing uterine contraction levels using image analysis |
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| AU2015283133B2 (en) | 2014-07-02 | 2019-05-16 | ObsEva SA | Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity |
| ES2716862T3 (es) | 2014-12-22 | 2019-06-17 | Ferring Bv | Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida |
-
2015
- 2015-06-10 AU AU2015283133A patent/AU2015283133B2/en active Active
- 2015-06-10 KR KR1020177001267A patent/KR102470283B1/ko active Active
- 2015-06-10 EA EA201790080A patent/EA031353B1/ru unknown
- 2015-06-10 WO PCT/EP2015/062881 patent/WO2016000920A1/en not_active Ceased
- 2015-06-10 CN CN201580047177.XA patent/CN106795110A/zh active Pending
- 2015-06-10 EP EP19204954.2A patent/EP3753921A1/en active Pending
- 2015-06-10 EP EP15730094.8A patent/EP3164384B1/en active Active
- 2015-06-10 US US14/735,215 patent/US9718772B2/en active Active
- 2015-06-10 CA CA2953722A patent/CA2953722C/en active Active
- 2015-06-10 EA EA201891873A patent/EA201891873A1/ru unknown
- 2015-06-10 ES ES15730094T patent/ES2774789T3/es active Active
- 2015-06-10 JP JP2016573776A patent/JP2017519015A/ja active Pending
- 2015-06-10 MX MX2016016751A patent/MX371068B/es active IP Right Grant
- 2015-06-10 CN CN202111228955.9A patent/CN114105850A/zh active Pending
- 2015-06-10 UA UAA201700678A patent/UA122210C2/uk unknown
- 2015-06-10 CN CN202111229040.XA patent/CN114105851A/zh active Pending
-
2016
- 2016-12-19 IL IL249652A patent/IL249652B/en unknown
-
2017
- 2017-05-25 US US15/604,816 patent/US10752583B2/en active Active
-
2020
- 2020-11-09 JP JP2020186785A patent/JP2021038236A/ja active Pending
-
2022
- 2022-11-18 JP JP2022184804A patent/JP2023018037A/ja active Pending
-
2024
- 2024-10-18 JP JP2024182585A patent/JP2025013885A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2953722C (en) | 2022-09-13 |
| JP2021038236A (ja) | 2021-03-11 |
| CN114105850A (zh) | 2022-03-01 |
| MX2016016751A (es) | 2017-08-08 |
| EP3753921A1 (en) | 2020-12-23 |
| ES2774789T3 (es) | 2020-07-22 |
| JP2023018037A (ja) | 2023-02-07 |
| EP3164384A1 (en) | 2017-05-10 |
| EA031353B1 (ru) | 2018-12-28 |
| JP2025013885A (ja) | 2025-01-28 |
| AU2015283133A1 (en) | 2017-02-16 |
| US20170320822A1 (en) | 2017-11-09 |
| AU2015283133B2 (en) | 2019-05-16 |
| UA122210C2 (uk) | 2020-10-12 |
| CA2953722A1 (en) | 2016-01-07 |
| EP3164384B1 (en) | 2019-12-04 |
| KR102470283B1 (ko) | 2022-11-23 |
| CN114105851A (zh) | 2022-03-01 |
| EA201790080A1 (ru) | 2017-06-30 |
| US10752583B2 (en) | 2020-08-25 |
| KR20170023961A (ko) | 2017-03-06 |
| EA201891873A1 (ru) | 2019-04-30 |
| US9718772B2 (en) | 2017-08-01 |
| IL249652A0 (en) | 2017-02-28 |
| JP2017519015A (ja) | 2017-07-13 |
| WO2016000920A1 (en) | 2016-01-07 |
| CN106795110A (zh) | 2017-05-31 |
| IL249652B (en) | 2021-09-30 |
| US20160002160A1 (en) | 2016-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016016751A (es) | (3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil] pirrolidin-3-ona o-metiloxima cristañina y métodos de uso de la misma. | |
| JOP20210109B1 (ar) | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك | |
| MX2021001091A (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. | |
| PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| MX2019003598A (es) | Formulaciones orales de derivados de pirrolidina. | |
| MX2018006223A (es) | Moduladores de ror-gamma. | |
| MX2020004894A (es) | Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina. | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| EA033250B1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет | |
| PH12017500089B1 (en) | Aldosterone synthase inhibitors | |
| TN2018000188A1 (en) | Isoindole compounds | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| CR20180056A (es) | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil] [3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona | |
| MD4780B1 (ro) | Urei asimetrice p-substituite şi utilizările medicale ale acestora | |
| MX2022014763A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| PH12016502568A1 (en) | Novel heterocyclic compound | |
| MX2016008968A (es) | Compuestos organicos. | |
| EA201991373A1 (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| MD20180049A2 (ro) | Compoziţie farmaceutică | |
| MX377481B (es) | Derivados de serina como agonistas del receptor de grelina. | |
| EA201892675A1 (ru) | Фармацевтическая композиция, содержащая этеплирсен | |
| RU2014104644A (ru) | Способ повышения эффективности лечения коров, больных острым гнойно-катаральным эндометритом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |